Abstract
The intestine has a major role in the digestion and absorption of nutrients, and gut barrier is the first defense line against harmful pathogens. Alteration of the intestinal barrier is associated with enhanced intestinal permeability and development of numerous pathological diseases including gastrointestinal and cardiometabolic diseases. Among the metabolites that play an important role within intestinal health, L Tryptophan (Trp) is one of the nine essential amino acids supplied by diet, whose metabolism appears as a key modulator of gut microbiota, with major impacts on physiological, and pathological pathways. Recently, emerging evidence showed that the Trp catabolism through one major enzyme indoleamine 2,3-dioxygenase 1 (IDO1) expressed by the host affects Trp metabolism by gut microbiota to generate indole metabolites, thereby altering gut function and health in mice and humans. In this mini review, I summarize the most recent advances concerning the role of Trp metabolism in host–microbiota cross-talk in health, and metabolic diseases. This novel aspect of IDO1 function in intestine will better explain its complex roles in a broad range of disease states where the gut function affects local as well as systemic health, and will open new therapeutic strategies.
Highlights
The prevalence of Western diet-induced metabolic syndrome (MetS) is booming, affecting more than 2 billion people worldwide and accounting for at least 3 million deaths per year [1]. This becomes worrying since MetS is the major contributor of the persistent increase in cardiovascular diseases (CVD), including myocardial infarction (MI), which is the main complication of atherosclerosis
We recently showed that IDO1 deletion or inhibition in the context of MetS improved insulin sensitivity, decreased endotoxemia, and chronic inflammation, and positively regulated lipid metabolism in liver, and adipose tissues
Data demonstrate the importance of indole metabolites in the re-establishment of intestinal epithelial barrier integrity in the context of intestinal inflammatory diseases and MetS
Summary
Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 970, Paris Cardiovascular Research Center, and Université Paris-Descartes, Paris, France. Emerging evidence showed that the Trp catabolism through one major enzyme indoleamine 2,3-dioxygenase 1 (IDO1) expressed by the host affects Trp metabolism by gut microbiota to generate indole metabolites, thereby altering gut function and health in mice and humans. In this mini review, I summarize the most recent advances concerning the role of Trp metabolism in host–microbiota cross-talk in health, and metabolic diseases.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
